MapLight Therapeutics (NAS: MPLT) key facts
- MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders.
- MapLight Therapeutics (NAS: MPLT)’s last known valuation is $704.3M (Oct 2025).
- It has raised $919.4M; the latest was PIPE ($8.1M) in Oct 2025.
- Notable investors include Novo Holdings, The Goldman Sachs Group.
- 2 institutional filers report fund marks on MapLight Therapeutics (NAS: MPLT) across 3 filings.
- Status: Publicly Held.
Who backs MapLight Therapeutics (NAS: MPLT)
2- ·Watch MapLight Therapeutics (NAS: MPLT): the Monday email on marks, rounds and moves
MapLight Therapeutics (NAS: MPLT) funding rounds
No funding rounds for MapLight Therapeutics (NAS: MPLT) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
MapLight Therapeutics (NAS: MPLT) valuation
MapLight Therapeutics (NAS: MPLT) is now publicly traded; this page covers its private-market history, where its last recorded valuation was $704 million (Oct 2025). Secondary trades, fund marks and rounds below are the private-market record; the listed share price is not tracked here.
Recent activity
In the last 90 days, MapLight Therapeutics (NAS: MPLT)'s record added 2 institutional fund marks (latest period Jul 2026).
Institutional holders and vehicles
2 SEC-registered funds reported 3 fair-value marks on MapLight Therapeutics (NAS: MPLT) between Apr 2026 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
MapLight Therapeutics (NAS: MPLT) investors
2 investors are on record for MapLight Therapeutics (NAS: MPLT), including Novo Holdings and The Goldman Sachs Group.
About MapLight Therapeutics (NAS: MPLT)
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
- Sector
- Healthcare
- HQ
- Burlington, MA, United States
- Founded
- 2018
- Employees
- 133
- Website
- maplightrx.com/
- Ownership
- Publicly Held
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
MapLight Therapeutics (NAS: MPLT)’s last known valuation, Oct 2025. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.
Institutional fund marks on MapLight Therapeutics (NAS: MPLT)
2 filers · latest Jul 20262 SEC-registered funds reported 3 fair-value marks on MapLight Therapeutics (NAS: MPLT) between Apr 2026 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View